ERBB2 and gastroesophageal junction adenocarcinoma: Untreated, locally advanced or metastatic HER2 positive G/GEJ adenocarcinoma. 81% male, 41% with age ≥ 65 years, 42% ECOG 0, 32% from Australia, Europe, Israel, and North America; 34% from Asia; and 34% from the rest of the world.